Opdivo nivolumab: Phase II data

Data from 33 immunotherapy-naive patients with refractory metastatic squamous cell carcinoma of the anal canal in an open-label, North American Phase II trial

Read the full 230 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE